Immunotherapy plus targeted therapy for metastatic anal cancer treatment
2 Views
administrator
07/05/23
Dr. Van Morris previews his presentation at the ESMO Virtual Congress 2020, and shares results from pilot study of anti-PD-1 antibody atezolizumab in combination with anti-VEGF antibody bevacizumab in patients with unresectable, metastatic anal cancer.
For more information, visit www.mdanderson.org/ESMO.
Request an appointment at MD Anderson by calling 1-877-632-6789 or online at: https://my.mdanderson.org/RequestAppointment
-
Category
Show more
Facebook Comments
No comments found